BridgeBio announced positive phase 3 results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), meeting primary and key secondary endpoints with 76% of treated patients achieving combined serum and urine calcium targets at Week 24 compared with 4% on standard therapy. The company said responders also normalized parathyroid hormone in a majority of patients and that encaleret was generally well tolerated. The encaleret dataset follows BridgeBio’s recent phase 3 win for another rare‑disease program, building momentum for a potential regulatory filing next year. BridgeBio framed the results as a meaningful clinical improvement for a small but high‑need patient population and signaled plans to pursue FDA review timelines. BridgeBio’s twin successes underscore the commercial and clinical value of targeted rare‑disease programs and are likely to focus investor attention on near‑term regulatory milestones.